Abstract
The terminology used in prescription-event monitoring for postmarketing surveillance is described. It has been developed by the Drug Safety Research Unit while processing records of 500,000 events associated with the use of new chemical entities by 460,000 patients in England since 1981.
Currently, the events are arranged in 24 classes which include 108 high-level terms and 1197 low-level terms. Low-level terms are used to code individual events reported by general practitioners, usually without an opinion about any possible causal relationship with a particular drug. Some low-level terms are lumped together as one high-level term when the event rates are estimated.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Finney DJ (1965) The design and logic of a monitor of drug use. J Chronic Dis 18: 77–98
Inman WHW, Rawson NSB, Wilton LV (1984) Prescription-event monitoring. In: Inman WHW (ed) Monitoring for drug safety. MTP Press, Lancaster, pp 213–235
Rawson NSB, Pearce GL, Inman WHW (1990) Prescription-event monitoring: methodology and recent progress. J Clin Epidemiol 43: 509–522
Joint Committee of ABPI, BMA, CSM and RCGP (1988) Guidelines on postmarketing surveillance. Br Med J 296: 399–400
Edwards IR (1992) The WHO database I. Drug Inf J 26: 447–480
Edwards IR, Lindquist M (1992) The WHO database II. Drug Inf J 26: 481–486
WHO (1991) International monitoring of adverse reactions to drugs adverse reaction terminology. WHO Collaborating Centre for International Drug Monitoring, Uppsala
National Technical Information Service (1992) Coding symbols for a thesaurus of adverse reaction terms (COSTART), 4th edn. National technical Information Service, Springfield, VA
WHO (1975) International classification of diseases, 9th edn. World Health Organization, Geneva
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kubota, K., Inman, W.H.W. Terminology in prescription-event monitoring. Eur J Clin Pharmacol 46, 497–500 (1994). https://doi.org/10.1007/BF00196104
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00196104